But their study of 45
cystic fibrosis patients showed that when the respiratory tract contains a more diverse community of microbes, the patient is less likely to harbor Pseudomonas aeruginosa, a key pathogen associated with later stages of cystic fibrosis.
Not exact matches
In lab experiments using tissue samples cultured from
cystic fibrosis patients, scientists at the UNC School of Medicine and the UNC Marsico Lung Institute have
shown that a new CF drug counteracts the intended beneficial molecular effect of another CF drug.
Lead UK author on the study, Professor Stuart Elborn, Dean of the School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, said: «The estimations we have made
show very positive news for
cystic fibrosis patients as the average survival age is increasing.
New research comparing
cystic fibrosis patients in the United States and Canada
showed that, although the
patients» nutritional status and lung function improved in both countries over the period from 1990 to 2013, the rate of improvement was faster in the United States.
A pulmonologist at the Medical Center was the first to
show that
patients with
cystic fibrosis have very little mucous in their airways — not as much as was previously thought.
The typical dosage of NAC given as an oral supplement in clinical trials is 600 mg b.i.d., although 200 mg t.i.d. has been
shown to provide benefit in just 8 weeks.27 On the other hand, doses as high as 1 gram t.i.d. have been used in
cystic fibrosis patients for 4 - 12 weeks with no adverse effects, and in AIDs
patients, oral NAC doses up to 8 grams / day did not cause clinically significant adverse reactions.42 43 44 45 46 47